Ezzahti M, Sijbrands E J G, Mulder M T, Roeters van Lennep J E
Department of Vascular Medicine, Erasmus MC, Rotterdam, The Netherlands.
Neth J Med. 2013 Jun;71(5):227-33.
Familial hypercholesterolaemia is a relatively frequently occurring disease that is strongly associated with vascular disease. Current treatment with cholesterol-lowering agents is partly effective but shows variable responses between patients with familial hypercholesterolaemia. Recently, new cholesterol-lowering drugs have been developed. Here we describe the most promising of these new agents for which results from phase 2 or phase 3 trials are available. We will discuss the data regarding lipid-lowering potential and safety issues and speculate about the potential reductions of the residual risk of statin-treated FH patients.
家族性高胆固醇血症是一种相对常见的疾病，与血管疾病密切相关。目前使用降胆固醇药物进行治疗部分有效，但在家族性高胆固醇血症患者之间显示出不同的反应。最近，已开发出新型降胆固醇药物。在此，我们描述这些新型药物中最有前景的药物，其已获得2期或3期试验结果。我们将讨论有关降脂潜力和安全性问题的数据，并推测他汀类药物治疗的家族性高胆固醇血症患者残余风险的潜在降低情况。
